Chemomab Therapeutics Reports Positive Phase 2 Nebokitug PSC Trial Results
Ticker: CMMB · Form: 6-K · Filed: Mar 27, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, biotech, drug-development, liver-disease
TL;DR
Chemomab's Nebokitug shows continued strong results in PSC Phase 2 trial extension.
AI Summary
On March 27, 2025, Chemomab Therapeutics Ltd. announced positive results from the open-label extension of its Phase 2 trial for Nebokitug in Primary Sclerosing Cholangitis (PSC). The trial showed continued broad and substantial improvements in key liver parameters for patients.
Why It Matters
Positive trial results for Nebokitug in PSC could indicate a promising new treatment option for patients suffering from this rare and serious liver disease.
Risk Assessment
Risk Level: medium — While results are positive, the drug is still in Phase 2 trials, and further studies are needed to confirm efficacy and safety.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Nebokitug (drug) — Investigational drug
- Primary Sclerosing Cholangitis (PSC) (disease) — Indication for Nebokitug
- March 27, 2025 (date) — Date of press release
FAQ
What specific key liver parameters showed improvement in the Nebokitug Phase 2 PSC open-label extension trial?
The filing states that the trial showed continued broad and substantial improvements in key liver parameters, but does not specify which ones.
What is the current stage of development for Nebokitug in treating Primary Sclerosing Cholangitis (PSC)?
Nebokitug is currently in a Phase 2 open-label extension trial for PSC.
When was the press release regarding the trial results issued?
The press release was issued on March 27, 2025.
What is the primary executive office location for Chemomab Therapeutics Ltd.?
The primary executive offices are located in Kiryat Atidim, Building 7, Tel-Aviv, Israel.
Does Chemomab Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Chemomab Therapeutics Ltd. files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 27, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).